​APN LifeSciences is dedicated to developing novel PET imaging diagnostic drugs and related testing tools for neurodegenerative diseases, including Alzheimer's and Parkinson's.​

​

Tau protein accumulation is highly associated with memory and cognitive function, making it a key disease indicator of disease severity. As such, Tau protein is considered the gold standard for dementia diagnosis. Furthermore, the accumulation of Tau protein in the brain can be used to assess the stage of the disease.